Medicare Will Cover New Class of Alzheimer's Drugs if Fully Approved by FDA, With Limits
Medically reviewed by Drugs.com.
By Cara Murez HealthDay Reporter
FRIDAY, June 2, 2023 -- Medicare will soon cover a new class of Alzheimer's drugs if they receive full approval from the U.S. Food and Drug Administration, with some key limits.
Along with being full approved, drug makers will also have to gather and keep data in a registry showing how the drugs are working in the real world, the U.S. Centers for Medicare and Medicaid Services announced Thursday.
““Alzheimer’s disease takes a toll on not just the people suffering from the disease but also on their loved ones and caregivers in a way that almost no other illness does. CMS has always been committed to helping people obtain timely access to innovative treatments that meaningfully improve care and outcomes for this disease,” CMS Administrator Chiquita Brooks-LaSure said in a statement announcing the change. "If the FDA grants traditional approval, CMS is prepared to ensure anyone with Medicare Part B who meets the criteria is covered."
The drugs in question -- Lecanemab (Leqembi) and Aduhelm -- have already been given accelerated approval to “fill an unmet medical need” while drug makers continue research on their effectiveness and safety. But neither drug has have received full, traditional approval.
Not everyone was thrilled with the idea of collecting real-world data in a registry.
In a statement, the Alzheimer’s Association called the registry requirement “an unnecessary barrier,” adding that the registry “should not be a requirement for coverage” of an FDA-approved treatment.
But the CMS said there is a “strong precedent” for using registries.
About 6 million Americans live with Alzheimer’s disease, which affects memory and cognitive abilities. There is no cure.
Sources
- U.S. Center for Medicare and Medicaid Services, news release, June 1, 2023
- Alzheimer's Association, news release, June 1, 2023
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted June 2023
Read this next
Scientists May Have Located Your Brain's 'Neural Compass'
TUESDAY, May 7, 2024 -- Researchers say they’ve identified a human “neural compass” -- a pattern of brain activity that helps prevent humans from becoming...
Gene Discovery Points to a New Form of Alzheimer's
TUESDAY, May 7, 2024 -- People who carry two copies of the gene mutation most strongly implicated in Alzheimer’s disease are almost certain to develop brain changes related...
Medicare Warnings Stop Nursing Homes From Overusing Antipsychotic Meds
FRIDAY, April 25, 2024 -- Warning letters sent by Medicare officials can prompt a decline in antipsychotic prescriptions for seniors with dementia, a new study finds. Letters...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
